Insmed Inc's experimental lung infection drug fared no better than a competing drug developed by Novartis and showed that patients taking Arikace displayed a smaller improvement in lung capacity than those on TOBI, Novartis's drug for the same infection. TOBI is cheaper and easier to use
You say no better but context is required. The trial included FORCED compliance on TOBI (multi times a day) vs. Arikace once a day. So the real question is what is real world compliance with TOBI? And if treatments are skipped how does it really stack up? But you know this already.
Sentiment: Strong Buy
you are not even worth answering if this is all you know about TOBI get lost. TOBI IS MORE Convenient DOES NOT HAVE TO BE REFRIGERATED LIKE ARIKACE DOES AND DOES NOT NEED A POWER OUTLET!
I though anyone who posted has at least a little knowledge. I am trying to HELP those here who think Arikace for cyc fibrosis will be anything but another wannabe.
fro Investors hub on the inferior results of Arikace
INSM Arikace: Sure, statistically non-inferior, but consistently worse than Tobi throughout 24 weeks of treatment! How about that for a marketing slogan?"
From investor sentiment report:
company's experimental lung-infection drug Arikace disappointed Wall Street.
So what: The trial showed that patients taking the once-daily drug Arikace had a smaller improvement in lung capacity than those treated with Novartis' (NYSE: NVS ) twice-daily competitor TOBI, triggering plenty of investor concern over Arikace's position in the market. While Insmed said that the trial met its main objective of showing that Arikace was not statistically inferior to TOBI, the lackluster results -- it isn't exactly superior -- suggest that the drug's sales potential is limited.